Quetiapine: recent developments in preclinical research

Marco Orsetti, Fabio Di Brisco, Massimo Mauro, Dario Dallorto, Piera Ghi

DOI: https://doi.org/10.7175/cmi.v4i1.536

Abstract

Quetiapine (QTP) is an atypical antipsychotic labelled for the treatment of patients with schizophrenia, bipolar mania and bipolar depression. Nevertheless, QTP has been tried across multiple diagnosis categories and seems to be used, among other atypical antipsychotics, in clinical practice for an expanding range of disorders such as major depression, substance abuse disorders, anxiety disorders, and borderline personality disorders. The present review focuses on papers which investigated the molecular mechanism(s) of QTP antidepressant effect. In particular, preclinical studies performed by coupling the chronic mild stress, an animal model of human depression with Affymetrix microarray technology, revealed that chronic QTP administration prevented the stress-induced up- or down-regulation of 42 genes involved in the central nervous system development or having a crucial role for viability of neural cells, like regulation of signal transduction, inorganic ion transport, membrane organisation, and neurite morphogenesis. Among these, Ptgs2, Hes5, Plcb1, Senp2, Gad1, and Marcks are presumably the effectors of the QTP clinical efficacy.

Keywords

Quetiapine; Depression; Gene regulation; Chronic mild stress

Full Text:

PDF

Refbacks

  • There are currently no refbacks.




© SEEd srl